Literature DB >> 16255757

The -670A > G polymorphism in the promoter region of the FAS gene is associated with necrosis in periportal areas in patients with chronic hepatitis C.

J Aguilar-Reina1, M Ruiz-Ferrer, M A Pizarro, G Antiñolo.   

Abstract

Evidence suggests that apoptosis of liver cells may play a significant role in the pathogenesis of hepatitis C virus (HCV) infection. One of the best characterized apoptotic pathway is that mediated by the death receptor Fas. Fas expression has been found to be up-regulated on hepatocytes in chronic HCV infection, particularly in periportal areas. Recently, two polymorphisms have been identified in the promotor region of the FAS gene, -1377G > A and -670A > G. We have evaluated the involvement of these variants in the susceptibility to HCV infection, the severity of liver damage and progression of fibrosis in chronic hepatitis C. A cohort of 197 patients with chronic hepatitis C and 100 controls were analysed for both polymorphisms by Fluorescence Resonance Energy Transfer using specific probes and the Lightcycler system. In addition, liver biopsies were taken in 167 patients and scored using the Knodell classification system. We have found that the allele frequencies and the distribution of both polymorphisms do not differ significantly in the HCV cohort and in the control population. Thus, none of the polymorphisms seems to be related with susceptibility to HCV infection. However, we have examined the possible association between the two variants and the grade of necroinflammatory activity and the stage of fibrosis and we have detected an under-representation of the -670A > G variant among those patients with higher Knodell's scores (P = 0.049) and necroinflammatory activity (P = 0.036). The -670A allele was associated with higher levels of periportal necrosis (P = 0.012). In conclusion, our findings suggest an association between the -670A > G polymorphism and the grade of necrosis in periportal areas in patients with chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16255757     DOI: 10.1111/j.1365-2893.2005.00639.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  7 in total

1.  Apoptosis-related Fas and FasL gene polymorphisms' associations with knee osteoarthritis.

Authors:  Melek Sezgin; İbrahim Ömer Barlas; Seyfi Yıldır; Gözde Türköz; Handan Çamdeviren Ankaralı; Günşah Şahin; Mehmet Emin Erdal
Journal:  Rheumatol Int       Date:  2013-02-08       Impact factor: 2.631

2.  Relation of the Fas and FasL gene polymorphisms with susceptibility to and severity of rheumatoid arthritis.

Authors:  Seyfi Yıldır; Melek Sezgin; Ibrahim Ömer Barlas; Gözde Türköz; Handan Çamdeviren Ankaralı; Günşah Şahin; Mehmet Emin Erdal
Journal:  Rheumatol Int       Date:  2013-06-09       Impact factor: 2.631

3.  Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer.

Authors:  Monica Ter-Minassian; Rihong Zhai; Kofi Asomaning; Li Su; Wei Zhou; Geoffrey Liu; Rebecca Suk Heist; Thomas J Lynch; John C Wain; Xihong Lin; Immaculata De Vivo; David C Christiani
Journal:  Carcinogenesis       Date:  2008-08-29       Impact factor: 4.944

4.  Association of FAS -670A/G and FASL -843C/T Gene Polymorphisms on Allograft Nephropathy in Pediatric Renal Transplant Patients.

Authors:  Pelin Ertan; Sevgi Mir; Nese Ozkayin; Afig Berdeli
Journal:  Iran J Pediatr       Date:  2010-12       Impact factor: 0.364

5.  Polymorphisms within Fas gene are not associated with occult hepatitis B virus infection: Polymorphisms within Fas gene in occult HBV infection.

Authors:  Mohammad Kazemi Arababadi; Adel Mohammadzadeh; Ali Akbar Pourfathollah; Derek Kennedy
Journal:  Hepat Mon       Date:  2011-01       Impact factor: 0.660

6.  FAS and FAS-Ligand Promoter Polymorphisms in Hepatitis B Virus Infection.

Authors:  Asadollah Mohammadi; Nader Tajik; Alireza Shah-Hosseini; Seyed Moayed Alavian; Zohreh Sharifi; Lida Jarahi
Journal:  Hepat Mon       Date:  2015-10-10       Impact factor: 0.660

7.  P53 rs1042522 and CD95 rs1800682 genetic variations in HCV-4a response to antiviral therapy.

Authors:  Ahmed A Abd-Rabou; Emad F Eskander; Mervat S Mohamed; Shaymaa M M Yahya; Ashraf El Sherbini; Olfat G Shaker
Journal:  Genes Dis       Date:  2015-02-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.